Table 1.
Characteristics of all 26 patients after liver transplantation for hepatocellular carcinoma included in the study cohort, including 20 patients with intrahepatic tumor dissemination and 10 patients with macrovascular invasion.
| Factors | All Patients (n = 26) |
Intrahepatic Dissemination (n = 20) |
Macrovascular Invasion (n = 10) |
|---|---|---|---|
| Sex | |||
| male | 21 (80.8%) | 16 (80.0%) | 7 (70.0%) |
| female | 5 (19.2%) | 4 (20.0%) | 3 (30.0%) |
| Age (years) | 58 (53–61) | 57 (53–61) | 57 (52–61) |
| Model for end-stage liver disease | 11 (8–16) | 10 (8–16) | 11 (8–16) |
| Hepatitis B virus infection | 8 (30.8%) | 8 (40.0%) | 2 (20.0%) |
| Hepatitis C virus infection | 18 (69.2%) | 14 (70.0%) | 7 (70.0%) |
| Alcoholic liver disease | 5 (19.2%) | 3 (15.0%) | 2 (20.0%) |
| AFP model | 3 (2–5) | 3 (2–5) | 3 (1–5) |
| Tumor number | – (≥10) a | – (≥10) a | 3.5 (1–>10) |
| Size of the largest tumor (cm) | 3.7 (2.6–5.2) | 3.4 (2.5–5.0) | 5.0 (2.5–5.0) |
| Alpha-fetoprotein concentration (ng/mL) | 24 (6–560) | 14 (3–571) | 167 (25–560) |
| Ca 19-9 concentration (U/mL) | 41 (21–47) | 39 (16–47) | 41 (35–45) |
| Poor tumor differentiation | 6 (23.1%) | 5 (25.0%) | 3 (30.0%) |
| Microvascular invasion | 16 (64.0%) | 10 (52.6%) | 9 (90.0%) |
| Macrovascular invasion | 10 (38.5%) | 4 (20.0%) | 10 (100.0%) |
| Neoadjuvant treatment | 10 (38.5%) | 7 (35.0%) | 4 (40.0%) |
| Total ischemic time (hours) | 9.5 (7.8–10.4) | 9.6 (8.5–10.5) | 8.6 (7.3–10.0) |
| Donor age | 51 (38–54) | 49 (37–53) | 50 (43–61) |
| Donor sex | |||
| male | 13 (50.0%) | 12 (60.0%) | 5 (50.0%) |
| female | 13 (50.0%) | 8 (40.0%) | 5 (50.0%) |
| Intraoperative PRBC transfusions (units) | 3.5 (2–5.5) | 4 (2–6) | 4 (2–5) |
| Intraoperative FFP transfusions (units) | 6 (4.5–10.0) | 6 (4–10) | 8 (5–10) |
Data are presented as number (%) or median (interquartile range); a = not calculated, as majority of tumors were classified as uncountable or numerous. Ca 19-9 PRBC = packed red blood cells; FFP = fresh frozen plasma.